Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was simply reporting an observation. The good news is, it has since been changed to $4.73
You may be disappointed, since it will be for November 30, while all the action took place at year end.
So yesterday, CYDY trading closed at $4.93 and the after 4 Forms T were at $5.00, and TDA chose to use $4.93 as the closing price.
Today CYDY trading closed at $4.73 and the after 4 Forms T were at $4.63, and TDA chose to use $4.63 as the closing price.
What's up with that ?
Speaking of Rolodexs, here is a word that seems to be missing from yours - Overseas. Said word, Overseas in turn has a Rolodex of its own, with words like Switzerland, Belgium, Germany, France, and another 100 plus more. I'm sure one of them would be happy to sell Vyrologix to the world, without a care about BP.
I am wondering what's wrong with a mechanical engineer ? Lots of recent posts here about Gilead, founded in 1987. Donald Rumsfeld became a director in 1988, and was later Chairman from 1997 to 2001. What medical school did he attend ??
Can't see what ACST has going for it, ca-pre failed. Need a double here to break even.
How does PTE look to you ?
Tech did not do well today, AAPL -$4.41, MSFT -$5.65, ORCL -$0.15, ADBE ouch -$19.38 meanwhile DJI +$437.80
There is also Inventia and PTE.
Apple Wins a Patent for an Interactive Laser Projection System for Presentations, a Virtual Desktop & more.
https://www.patentlyapple.com/patently-apple/2020/12/apple-wins-a-patent-for-an-interactive-laser-projection-system-for-presentations-a-virtual-desktop-more.html
As I shared the following recently with you -
Oh, I love AAPL. It provided me with my first $ignificant Milestone, and is about to do a repeat performance, so I am as they say, a "fan boy".
Talk about iCar can only help my portfolio even more.
And this with someone else -
I did not keep up with portfolio concentration, so AAPL is now 87% of my portfolio. The way I see it, is that with that much concentration, if there is a market correction of up to 40%, it won't affect me tremendously. My Avg. cost is 20.98, so I am up 545%, having started buying in Jan.2010.
Of course, with that much of a concentration, I do not have much left over for diversification.
My last trade was Nov.18, bought on MARGIN 3,000 @ $118.98 = $356,210. On 12/24, sold 2,750K @ $132.55 = $364,520 So I came out with +250 shares, and $8,310.00 before cost of margin, say $1,524.00 (356210 x 40 days @ 3.85%)
Looking forward to rinse and repeat, but will probably add other tech, next year.
Tried this in 2019, but HAL got the better of me.
Looking to add 5K ORCL tomorrow, hopefully under $65.00 then probably sell the $66 Jan15 options to cover margin, and collect my $1,200.00 divvy on the way out.
Happy new year to all, and a bright and covid free 2021.
Neat trick, posting this on 12/24 while I see it in today's issue of WSJ 12/26&27.
B-O, that is the front end, you short 2000 at $5 and have to cover at $10. But you don't have the cash ($10K) from the sale (folks don't usually have proceeds sitting in their account), and now you have to find $20K, so the broker sells other stock you own, and if they have gains in those stocks, then they have a tax situation, if it happens in the next 4 days. Hope that happens.
I have seen shorts escape before, laughing all the way to the bank. As of 12/15, short interest was 27,043,506 which I suspect has risen, since we closed that day @ $3.46, and subsequently went up to $7.00 so during the next 7 trading days, my guess is we hit 28M short. It would be interesting to see what would happen if we were all to place a sell order for 10 shares @ $20.00 for Monday.
He gets it, the Batteries.
https://seekingalpha.com/article/4396067-quick-perspective-on-apple-car
Merry Christmas.
Some light in the tunnel. Merry Christmas to all.
FDA Provides Guidance for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is Unblinded
Download as PDFDecember 24, 2020 7:46pm EST
The agency will also consider eINDs for patients in other hospitals who qualify for inclusion criteria similar to CD12
The CD12 trial completed enrollment with 394 patients on December 16
VANCOUVER, Washington, Dec. 24, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company", a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the U.S. Food and Drug Administration (“FDA”) provided guidance to the Company to add an open-label extension to its Phase 3 trial (“CD12”) and specific criteria for the continuation of eINDs for patients meeting the inclusion/exclusion criteria of CD12.
The CD12 protocol will be amended for adding the open-label arm extension and submitted to the FDA on Monday, December 28, 2020. Upon clearance, each CD12 participating clinical trial site will have the option of enrolling additional qualified patients, with all patients receiving leronlimab. Treatment of qualified patients will continue until the trial’s data is unblinded.
The FDA also provided specific guidance for the benefit of physicians seeking an eIND for COVID-19 patients, which must first meet the inclusion/exclusion criteria of the CD12 study, and such criteria will be provided to them in the form of a checklist.
Mahboob Rahman, M.D., Ph.D., Chief Scientific Officer and Head of Clinical Development for CytoDyn, stated, “We are pleased that at a time when COVID-19 cases and mortality continue to increase, the FDA’s thoughtful advice will allow a specified subset of patients access to leronlimab, while we await the results of the randomized placebo-controlled portion of the Phase 3 study. We are committed to work with the FDA and the health care providers to improve the outcomes of COVID patients.”
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are very thankful to the FDA for providing guidance on accessing our drug pending the results of CD12, especially during these unprecedented times. CytoDyn will provide the precise requirements for potential participation in the new CD12 open-label extension and physicians seeking eINDs, while we eagerly await the unblinding of the data. The results of our CD10 trial will not support an eIND request.”
Remember the market closes at 1:00 p.m. EST tomorrow. Recall GM and Ford a few years ago. Car manufacturing is too fraught with problems. No, battery technology is where the $$ are. For the month so far I have bought 2 x 32 of AAA and 2 x 40 of AA. Next time you buy a Duracell battery, remember you are rewarding Warren Buffet's Berkshire Hathaway.
Make a car, no, but they may partner up to supply the electronics - I'll take 2.
Even in after hours today, doubt it will get to $132.00
We need to find out can the FDA be held accountable in a court of law.
AMRN took the FDA to court TWICE and won both times.
In case I don't read this board for a few days, here's wishing you all stay safe, and have a reverent Christmas. May you not have any tax loss selling, and may the force be with you i.e. the January effect.
I still don't get the heavy reliance on RLF. All NeuroRX is getting from that is a slice of the Aviptadil profits, but it seems that some folks are including RLF in the BRPA deal ???
Ain't that something, on the day TSLA enters the S&P 500, amidst fears that folks were selling AAPL to buy TSLA, somehow news about the iCar comes out. I smell a leak. Oh Tim you're making Steve really proud of you. Tomorrow is going to be a fun day with AAPL, already hit $132 after hours, hope it bounces more.
This is so funny. Rumor was that folks were going to sell AAPL to buy TSLA, since TSLA was going to be included in the S&P 500 today, 12/21. BUT somehow, the news of the iCar gets rolled out today, TSLA drops, AAPL rises. Elon Musk needs to realize that Tim Cook is a corporate descendant of Steve Jobs.
From TDA -
Velodyne Lidar shares are trading higher following a report indicating Apple is targeting electric car production as early as 2024 and is expected to partner with outside lidar companies for some sensors.
Since it would be as of 12/15, I would not be surprised if it was in the region of 30M.
I blinked and it was gone. Looks like the next step is $5.20
Looks like today we close between $4.90 and $4.94
Level II is showing an ask of 100,000 @$5.That will wait for next week.
That is the result of the 5 to 1 reverse split of September 11.
Tomorrow should be very interesting, with 187,220 option contracts @130 outstanding. Hope it happens so that my 10 contracts get called since I really need to reduce my margin. I think it is going to be exceedingly difficult.
Anyone notice we had a Harami on Monday ?
https://ih.advfn.com/stock-market/USOTC/cytodyn-qb-CYDY/chart
Fortunately, it seems to be like the proverbial "one in a million".
I'll also hunker down and wait to see if a DNA vaccine gets approved, as opposed to the mRNA's around. While the daunting task of vaccinating 300M+ folks goes on, there will be millions who get sick and need hospitalization, which is why I think the real money is to be made from the therapeutic sector - Inovio INO, Humanigen HGEN, Cytodyn CYDY, Relief RLFTF, Revive RVVTF, Biocryst BCRX.
BCRX interests me, since I tend to follow the Baker Brothers, who did well this month with ALXN, kind of making up for the drubbing they took on AMRN (which I am now selling off for tax purposes).
https://www.dailymail.co.uk/health/article-9060697/Alaska-healthcare-worker-suffered-allergic-reaction-Pfizers-coronavirus-vaccine.html
Guess the allergic reactions are going to be a problem.
There is another Form D today.
Total Offering Amount $1,176,000 USD
or
Total Amount Sold $0 USD
Total Remaining to be Sold $1,176,000 USD
or
Clarification of Response (if Necessary):
Offering related to the issuance of stock options to accredited investors to acquire 350,000 shares of common stock, at an exercise price of 3.36 per share, issued for compensatory purposes to service providers to the Company.
https://sec.report/Document/0001807094-20-000028/
Perhaps you can answer a question that has been nagging me. I keep seeing posters saying "2 weeks to analyze the data".
If the endpoint of the trial is mortality, why would it take 2 weeks to count how many participants are alive ?
These 53 Restaurant Chains Are on the Brink of Disappearing Entirely.
https://explore.simpli.com/these-restaurant-chains-are-on-the-brink-of-disappearing-entirely-copy/2
Now that is the definition of irrational exuberance - servicing a declining number of restaurants.
Options market does not seem enthusiastic about >$125.